Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.
Sean Maduck net worth and biography

Sean Maduck Biography and Net Worth

Mr. Maduck was named Corcept’s Chief Commercial Officer in 2020. Prior to that he was Corcept’s Senior Vice President, Commercial. Before that, he was the company’s Vice President, Sales & Marketing. Mr. Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R. Hambrecht + Company. He currently serves on the Board of Directors of the Cancer Support Community – San Francisco Bay Area. Mr. Maduck earned an AB from Dartmouth College, a BE in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College and a Masters in Management from the Stanford Graduate School of Business.

What is Sean Maduck's net worth?

The estimated net worth of Sean Maduck is at least $1.31 million as of December 1st, 2022. Mr. Maduck owns 56,462 shares of Corcept Therapeutics stock worth more than $1,313,306 as of January 30th. This net worth evaluation does not reflect any other investments that Mr. Maduck may own. Learn More about Sean Maduck's net worth.

What is Sean Maduck's salary?

As the Insider of Corcept Therapeutics Incorporated, Mr. Maduck earned a total compensation package of $4,545,181.00 in 2021. Mr. Maduck earned a salary of $519,451.00, a bonus of $309,375.00, options awards of $3,716,355.00, and no other miscellaneous compensation. Learn More on Sean Maduck's salary.

How do I contact Sean Maduck?

The corporate mailing address for Mr. Maduck and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected] Learn More on Sean Maduck's contact information.

Has Sean Maduck been buying or selling shares of Corcept Therapeutics?

Sean Maduck has not been actively trading shares of Corcept Therapeutics during the last quarter. Most recently, Sean Maduck sold 625 shares of the business's stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $25.28, for a transaction totalling $15,800.00. Following the completion of the sale, the insider now directly owns 56,462 shares of the company's stock, valued at $1,427,359.36. Learn More on Sean Maduck's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Lyon (CAO), Sean Maduck (Insider), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 13 times. They sold a total of 507,931 shares worth more than $13,065,397.88. The most recent insider tranaction occured on December, 1st when insider Sean Maduck sold 625 shares worth more than $15,800.00. Insiders at Corcept Therapeutics own 18.6% of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 12/1/2022.

Sean Maduck Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2022Sell625$25.28$15,800.0056,462View SEC Filing Icon  
11/10/2022Sell25,000$25.57$639,250.0056,462View SEC Filing Icon  
10/3/2022Sell25,000$25.64$641,000.0056,462View SEC Filing Icon  
8/9/2022Sell200$28.70$5,740.0040,024View SEC Filing Icon  
7/18/2022Sell25,000$27.37$684,250.0040,024View SEC Filing Icon  
10/5/2021Sell637$20.00$12,740.00View SEC Filing Icon  
10/1/2021Sell24,363$20.00$487,260.00View SEC Filing Icon  
9/1/2021Sell25,000$21.40$535,000.0065,024View SEC Filing Icon  
8/3/2021Sell25,000$21.18$529,500.0065,024View SEC Filing Icon  
7/7/2021Sell25,000$22.19$554,750.00View SEC Filing Icon  
2/16/2021Sell8,989$28.25$253,939.2533,424View SEC Filing Icon  
2/11/2021Sell3,400$29.78$101,252.0033,424View SEC Filing Icon  
12/12/2018Sell60,000$19.01$1,140,600.0065,015View SEC Filing Icon  
See Full Table

Sean Maduck Buying and Selling Activity at Corcept Therapeutics

This chart shows Sean Maduck's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $23.26
Low: $22.90
High: $23.45

50 Day Range

MA: $22.37
Low: $19.95
High: $26.10

2 Week Range

Now: $23.26
Low: $16.79
High: $30.14


270,300 shs

Average Volume

595,728 shs

Market Capitalization

$2.50 billion

P/E Ratio


Dividend Yield



Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
click here now to get all the chilling details.